



# Illuminating the people and science shaping the world of healthcare

FEBRUARY 2021



## Top 5 Doctors Specialties Working in

### Diabetes

- ENDOCRINOLOGY, DIABETES & METABOLISM
- CARDIOVASCULAR DISEASE
- ALLERGY & IMMUNOLOGY
- NEPHROLOGY
- HYPERTENSION SPECIALIST



# 1,171,943

## Doctors working on Diabetes

## Top institutions doing work in

### Diabetes

- University Glasgow
- University of Toronto Temerty Faculty of Medicine
- UNC Health Care
- Harvard T.H. Chan School of Public Health
- University of Gothenburg
- University of Copenhagen
- Keck School of Medicine of University of Southern CA
- UT Health San Antonio

## Top 10 influential doctors in Diabetes

<p><b>Jens Juul Holst MD</b></p> <p><b>SPECIALTY</b> Diabetes</p> <p><b>NPI</b> Professor University of Copenhagen Copenhagen, Denmark, 01017</p>	<p><b>PUBLICATIONS</b></p> <p>Total: 1822</p> <p>Citations: 99.4 k</p> <p>h-index: 259</p> <p>Social Media Mentions: 2.7 k</p>	<p><b>CLINICAL TRIALS</b></p> <p>Total: 140</p> <p>Completed: 117</p> <p>Terminated: 117</p> <p>In-progress: 19</p>	
<p><b>Naveed Sattar</b></p> <p>FRCP, FRSE, FRCPATH, PHD, FMEDSCI</p> <p><b>SPECIALTY</b> Endocrinology, Diabetes &amp; Metabolism, Cardiovascular Disease</p> <p><b>NPI</b> Professor University of Glasgow Glasgow, United Kingdom, G12 8QQ</p>	<p><b>PUBLICATIONS</b></p> <p>Total: 1467</p> <p>Citations: 94.4 k</p> <p>h-index: 232</p> <p>Social Media Mentions: 15.6 k</p>	<p><b>CLINICAL TRIALS</b></p> <p>Total: 39</p> <p>Completed: 29</p> <p>Terminated: 29</p> <p>In-progress: 7</p>	
<p>Bernard Zinman</p>	<p>John B Buse</p>	<p>Melanie J. Davies</p>	<p>Frank B. Hu</p>
<p>Julio Rosenstock</p>	<p>Kamlesh Khunti</p>	<p>Chantal Mathieu</p>	<p>Darren Keith McGuire</p>

## Top 5 social media influencing doctors in Diabetes

<p><b>John B Buse PhD, MD</b></p> <p><b>SPECIALTY</b> Endocrinology, Diabetes &amp; Metabolism</p> <p><b>NPI</b> 1336164680</p> <p><b>Chief</b> University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27514</p>	<p><b>Bernard Zinman CM, MD, FACP, FRCPC</b></p> <p><b>SPECIALTY</b> Endocrinology, Diabetes &amp; Metabolism</p> <p><b>NPI</b></p> <p><b>Professor</b> University of Toronto Toronto, Canada, M5S 1A1</p>																				
<table border="1"> <tr> <td><b>PUBLICATIONS</b></td> <td><b>CLINICAL TRIALS</b></td> </tr> <tr> <td>Total: 581</td> <td>Total: 48</td> </tr> <tr> <td>Citations: 76.2 k</td> <td>Completed: 45</td> </tr> <tr> <td>h-index: 170</td> <td>Terminated: 45</td> </tr> <tr> <td>Social Media Mentions: 6.7 k</td> <td>In-progress: 1</td> </tr> </table>	<b>PUBLICATIONS</b>	<b>CLINICAL TRIALS</b>	Total: 581	Total: 48	Citations: 76.2 k	Completed: 45	h-index: 170	Terminated: 45	Social Media Mentions: 6.7 k	In-progress: 1	<table border="1"> <tr> <td><b>PUBLICATIONS</b></td> <td><b>CLINICAL TRIALS</b></td> </tr> <tr> <td>Total: 782</td> <td>Total: 37</td> </tr> <tr> <td>Citations: 58.6 k</td> <td>Completed: 32</td> </tr> <tr> <td>h-index: 170</td> <td>Terminated: 32</td> </tr> <tr> <td>Social Media Mentions: 6.6 k</td> <td>In-progress: 4</td> </tr> </table>	<b>PUBLICATIONS</b>	<b>CLINICAL TRIALS</b>	Total: 782	Total: 37	Citations: 58.6 k	Completed: 32	h-index: 170	Terminated: 32	Social Media Mentions: 6.6 k	In-progress: 4
<b>PUBLICATIONS</b>	<b>CLINICAL TRIALS</b>																				
Total: 581	Total: 48																				
Citations: 76.2 k	Completed: 45																				
h-index: 170	Terminated: 45																				
Social Media Mentions: 6.7 k	In-progress: 1																				
<b>PUBLICATIONS</b>	<b>CLINICAL TRIALS</b>																				
Total: 782	Total: 37																				
Citations: 58.6 k	Completed: 32																				
h-index: 170	Terminated: 32																				
Social Media Mentions: 6.6 k	In-progress: 4																				
<table border="1"> <tr> <td><b>OPEN PAYMENTS</b></td> <td><b>CONGRESSES</b></td> </tr> <tr> <td>Total: 2.1 m</td> <td>Total: 7</td> </tr> <tr> <td>Avg. per year: 352.3 k</td> <td></td> </tr> </table>	<b>OPEN PAYMENTS</b>	<b>CONGRESSES</b>	Total: 2.1 m	Total: 7	Avg. per year: 352.3 k		<table border="1"> <tr> <td><b>OPEN PAYMENTS</b></td> <td><b>CONGRESSES</b></td> </tr> <tr> <td>Total: 0</td> <td>Total: 12</td> </tr> <tr> <td>Avg. per year: 0</td> <td></td> </tr> </table>	<b>OPEN PAYMENTS</b>	<b>CONGRESSES</b>	Total: 0	Total: 12	Avg. per year: 0									
<b>OPEN PAYMENTS</b>	<b>CONGRESSES</b>																				
Total: 2.1 m	Total: 7																				
Avg. per year: 352.3 k																					
<b>OPEN PAYMENTS</b>	<b>CONGRESSES</b>																				
Total: 0	Total: 12																				
Avg. per year: 0																					
<p><b>PUBLICATIONS</b></p> <ul style="list-style-type: none"> <li>Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes.</li> </ul> <p><b>CLINICAL TRIALS</b></p> <p>Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.</p>	<p><b>PUBLICATIONS</b></p> <ul style="list-style-type: none"> <li>Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes:...</li> </ul> <p><b>CLINICAL TRIALS</b></p> <p>Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.</p>																				
<p><b>Naveed Sattar</b></p>	<p><b>Monika Maria Safford</b></p>	<p><b>Darren Keith McGuire</b></p>																			